Imaging method and system based on dynamic glucose enhancement technology

By combining T1ρ-DGE, T2WI and CET1WI imaging methods, abnormal glucose metabolism areas are identified, which solves the problem of inaccurate glioma boundary identification in existing technologies and achieves non-invasive and safe quantitative guidance of the tumor surgical resection range.

CN120661088APending Publication Date: 2025-09-19AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202510870940.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-26
Publication Date
2025-09-19

AI Technical Summary

Technical Problem

When identifying glioma boundaries, existing technologies such as magnetic resonance imaging (MRI) cannot accurately display the true tumor boundaries, making surgical resection difficult. Traditional PET imaging is also limited by radiation damage and high costs.

Method used

By performing T1ρ-DGE, T2WI and CET1WI imaging on the patient's head, areas of abnormal glucose metabolism are identified. By combining the signal amplification differences between T1ρ-DGE and CET1WI imaging, a quantitative guide to the surgical resection range is generated.

Benefits of technology

It improves the accuracy of identifying abnormal glucose metabolism areas, provides non-invasive and safe image quality, overcomes the signal changes caused by edema and blood-brain barrier damage, quantitatively guides the scope of surgical resection, and improves surgical accuracy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120661088A_ABST
    Figure CN120661088A_ABST
Patent Text Reader

Abstract

The invention provides an imaging method and system based on a dynamic glucose enhancement technology. The method comprises the following steps: firstly, scanning the skull of a patient to carry out magnetic resonance imaging to respectively obtain a T1rho-DGE image, a T2WI image and a CET1WI image; secondly, registering the T2WI image and the CET1WI image, and re-sampling to obtain a T1rho-DGE image to obtain a non-overlapping region, namely a mismatching region; then calculating the signal amplification of an unmatched region in T1rho-DGE imaging compared with a normal brain tissue region on the opposite side; and finally, based on the signal amplification difference between the T1rho-DGE imaging and the CET1WI imaging, identifying the glucose abnormal metabolic region. Furthermore, an operation resection range guidance scheme can be generated according to the positioning result of the glucose abnormal metabolic region in a quantified mode. The imaging method and system have the advantages of being noninvasive, safe and capable of improving surgical treatment decision accuracy, and key guidance can be provided for planning the glioma surgical resection range.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical imaging technology and relates to an imaging method and system based on dynamic glucose enhancement technology. Background Art

[0002] Recent studies have shown that dynamic glucose enhancement (DGE) can be used to reveal the true glucose metabolism within tumors. By injecting a solution containing a certain ratio of dextran, delayed enhancement can be produced in the tumor region, distinct from that observed with gadolinium contrast agents. This technique captures the intracellular and extracellular exchange of hydroxyl groups, reflecting the glucose uptake and metabolism within and outside tumor tissue. One such technique is T1ρ-weighted dynamic glucose enhancement (T1ρ-DGE). Following in vivo glucose injection, the water signal changes due to the chemical exchange between water protons and glucose protons. Based on this principle, T1ρ-DGE indirectly detects glucose or its analogs by measuring changes in the water signal after selective radiofrequency irradiation. By utilizing biodegradable contrast agents such as dextran, T1ρ-DGE MRI has great potential for studying the physiological and metabolic characteristics of cancer. Preliminary studies of T1ρ-DGE in tumors have demonstrated a mismatch between T1ρ-DGE and contrast-enhanced T1-weighted imaging (CET1WI) in some cases.

[0003] Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. However, due to the unclear boundaries of GBM lesions, it is challenging for neurosurgeons to achieve complete tumor resection. Therefore, accurately visualizing the boundaries of gliomas to achieve complete or protective resection has always been an important goal to improve patient prognosis. Generally, magnetic resonance imaging, especially CET1WI, is the most commonly used method to visualize GBM. However, an increasing number of studies have reported that the enhancement boundary observed on CET1WI does not accurately represent the true tumor boundary, but rather represents the leakage of gadolinium into the extracellular space (ECS) through the blood-brain barrier destroyed by the tumor. The metabolic edge of the tumor represents its true boundary. Positron emission tomography (PET) using 18F-labeled fluorodeoxyglucose (FDG) has been widely used to image glucose uptake. However, its application is limited by the radiation damage and high cost of the isotope. Summary of the Invention

[0004] The present invention aims to overcome the shortcomings and deficiencies of the prior art by providing an imaging method and system based on dynamic glucose enhancement technology. The present invention first performs magnetic resonance imaging (MRI) on a patient's skull scan to obtain T1ρ-DGE imaging, T2WI imaging, and CET1WI imaging. The T2WI and CET1WI images are then registered and resampled to the T1ρ-DGE image to obtain non-overlapping regions, known as mismatched regions. The signal amplification of the mismatched regions in the T1ρ-DGE image compared to the contralateral normal brain tissue region is then calculated. Finally, based on the difference in signal amplification between the T1ρ-DGE and CET1WI images, areas of abnormal glucose metabolism are identified. Furthermore, the results of quantifying the location of the abnormal glucose metabolism areas can be used to generate guidance for the extent of surgical resection. The imaging method and system of the present invention overcome the shortcomings of single T1ρ-DGE imaging that is susceptible to signal changes caused by edema and blood-brain barrier damage by integrating the imaging methods of T1ρ-DGE imaging, T2WI imaging, and CET1WI imaging. By comparing the signal amplification differences between T1ρ-DGE imaging and CET1WI imaging in mismatched areas, the accuracy of identifying abnormal glucose metabolism areas is directly improved, providing a reliable basis for quantitative guidance of the surgical resection range.

[0005] The purpose of the present invention can be achieved by the following solutions:

[0006] In a first aspect, the present invention provides an imaging system based on dynamic glucose enhancement technology, comprising:

[0007] Module M1: Perform magnetic resonance imaging on the patient's head to obtain T1ρ-DGE imaging, T2WI imaging, and CET1WI imaging;

[0008] Module M2: align T2WI imaging with CET1WI imaging and resample to T1ρ-DGE imaging to obtain non-overlapping areas, which are the mismatch areas;

[0009] Module M3: Calculate the signal increase of the mismatched area compared with the contralateral normal brain tissue area in T1ρ-DGE imaging;

[0010] Module M4: Identify areas of abnormal glucose metabolism based on the difference in signal amplification between T1ρ-DGE imaging and CET1WI imaging.

[0011] In the present invention, the T1ρ-DGE imaging is T1ρ-weighted dynamic glucose-enhanced imaging, T2WI imaging is T2-weighted imaging, and CET1WI is contrast-enhanced T1-weighted imaging. T1ρ-DGE imaging involves the injection of a certain proportion of dextrorotatory glucose solution, which can cause delayed enhancement in the tumor area, unlike T2WI imaging following injection of a gadolinium contrast agent. This technology reflects the glucose uptake and metabolism inside and outside tumor tissue cells by capturing the intracellular and extracellular hydroxyl exchange.

[0012] As an embodiment of the present invention, in module M1, the pretreatment of T1ρ-DGE imaging includes: injecting a dextrorotatory glucose solution into the patient's elbow vein; wherein the injection dose is 2.5-3.5 mL / kg and the injection rate is 0.05-0.15 mL / min. In some embodiments, the dextrorotatory glucose solution is dextrorotatory glucose dissolved in phosphate buffered saline (PBS; 10 mM H2PO4 - / HPO4 2- , pH = 7.2) and placed in a nuclear magnetic resonance tube. All solutions were set at 37°C.

[0013] Furthermore, the mass percentage of the D-glucose solution is 5%-10%.

[0014] As one embodiment of the present invention, in module M1, the pretreatment for CET1WI imaging includes: injecting a gadolinium solution into the patient's cubital vein; the injection dose is 0.05-0.15 mmol / kg, and the injection rate is 1.5-2.5 mL / s. Preferably, the gadolinium solution is Gd-DTPA (Magnevist; Bayer-Schering, Berlin, Germany).

[0015] Furthermore, the concentration of the gadolinium solution is 0.5 mmol / mL.

[0016] As an embodiment of the present invention, in module M1, the T2WI imaging is a plain scan, and does not require the injection of contrast agents.

[0017] As an embodiment of the present invention, in module M1, the T1ρ-DGE imaging acquisition parameters are as follows: repetition time (TR) / echo time (TE) = 2300 / 69.6 ms, field of view (FOV) = 60×36 mm, matrix = 96×40, layer thickness / layer spacing = 2.8 / 0.2 mm, number of excitations (NEX) = 6, spin lock frequency = 500 Hz, spin lock time (TSL) = 50 ms, number of measurements = 35; the T2WI imaging acquisition parameters are as follows: The data are as follows: TR / TE=7964 / 73.2 ms, FOV=60×42 mm, matrix=192×160, slice thickness / slice spacing=1.8 / 0.2 mm, echo train length (ETL)=24, NEX=2; the CET1WI imaging acquisition parameters are as follows: TR / TE=1750 / 16.1 ms, FOV=60×42 mm, matrix=288×256, slice thickness / slice spacing=2.8 / 0.2 mm, ETL=6, NEX=2.

[0018] As an embodiment of the present invention, in module M3, the signal increase is an increase in the intensity ratio (DGEρ).

[0019] Furthermore, the intensity ratio DGEρ is the change in relative signal intensity (SI) at time point t in T1ρ-DGE imaging, and its calculation formula is as follows:

[0020]

[0021] Where S(t) is the signal intensity at time t, and Sref is the reference signal intensity obtained before the injection of the D-glucose solution. Specifically, the intensity ratio DGEρ is determined by the relative SI difference between the T1ρ-DGE SI (S(t)) obtained at time t and the reference signal (Sref) obtained by averaging the T1ρ-DGE SI before glucose injection.

[0022] As an embodiment of the present invention, in module M4, the difference in signal amplification between the T1ρ-DGE imaging and the CET1WI imaging is that the signal amplification of the T1ρ-DGE imaging is greater than 20% and no signal amplification is observed in the CET1WI imaging.

[0023] In the present invention, a surgical resection range guidance plan is generated based on the quantitative positioning results of the abnormal glucose metabolism area, and the abnormal glucose metabolism area is defined as the peritumoral area.

[0024] In a second aspect, the present invention provides an imaging method based on dynamic glucose enhancement technology, comprising the following steps:

[0025] Step S1: Perform magnetic resonance imaging on the patient's head to obtain T1ρ-DGE imaging, T2WI imaging, and CET1WI imaging;

[0026] Step S2: registering the T2WI imaging with the CET1WI imaging and resampling them to T1ρ-DGE imaging to obtain the non-overlapping area, which is the mismatch area;

[0027] Step S3: calculating the signal increase of the mismatched area compared with the contralateral normal brain tissue area in T1ρ-DGE imaging;

[0028] Step S4: Identify abnormal glucose metabolism areas based on the difference in signal amplification between T1ρ-DGE imaging and CET1WI imaging.

[0029] Compared with the prior art, the present invention has the following beneficial effects:

[0030] 1. The present invention uses a non-invasive imaging method and system to identify areas of abnormal glucose metabolism and obtain the actual glucose metabolism status within the tumor, thereby providing early infiltration boundaries of gliomas that cannot be displayed by traditional imaging, and quantifying the surgical resection range to generate a surgical resection range guidance plan, thereby improving the accuracy of the surgical resection range of gliomas and, to a certain extent, improving the therapeutic effect of surgery. It has the advantages of being non-invasive, safe, and improving the accuracy of surgical treatment decisions, and can provide key guidance for planning the surgical resection range of gliomas.

[0031] 2. The imaging method and system of the present invention utilizes D-glucose solution as a contrast agent. This readily available, non-allergenic contrast agent mitigates the risk of nephrogenic fibrosis and eliminates the need for radioactive isotopes, thus avoiding the radiation exposure associated with existing imaging methods. Its biodegradability offers significant safety advantages, as well as superior image quality and the ability to maintain an enhanced state for extended periods. Furthermore, by optimizing the concentration of the D-glucose solution, the present invention significantly enhances the visual quality of imaging.

[0032] 3. The imaging method and system of the present invention overcome the shortcomings of single T1ρ-DGE imaging, which is susceptible to signal changes caused by edema and blood-brain barrier disruption, by integrating T1ρ-DGE imaging, T2WI imaging, and CET1WI imaging. By comparing the difference in signal amplification between T1ρ-DGE imaging and CET1WI imaging in mismatched areas, it is possible to distinguish which areas are truly abnormal metabolic zones, thereby directly improving the accuracy of identifying abnormal glucose metabolism zones. In particular, it is possible to identify early-stage tumor infiltration areas with abnormal metabolic activity, even though the blood-brain barrier has not yet been significantly disrupted and CET1WI imaging cannot show. This provides a reliable basis for quantitative guidance on the extent of surgical resection. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Other features, objects and advantages of the present invention will become more apparent upon reading the detailed description of non-limiting embodiments with reference to the following drawings:

[0034] Figure 1 Schematic diagram of the process of an embodiment;

[0035] Figure 2 Schematic diagram of the average signal value test of the model of D-glucose solution with different concentrations in the embodiment;

[0036] Figure 3 Schematic diagram of signal measurement of a T1ρ / CET1 image mismatch ROI in this embodiment; Figure a is a CET1WI image, Figure b is a T2WI image, Figure c is a T1ρ-DGE image, Figure d is a schematic diagram of delineation in a T1ρ-DGE image, and Figure e is a dynamic curve change of a T1ρ / CET1 mismatch ROI;

[0037] Figure 4 Figure 1 is a localization diagram of the T1ρ / CET1 image mismatch region in the embodiment; Figure a is a schematic diagram of the T1ρ / CET1 image mismatch region, Figure b is a schematic diagram of establishing a coordinate system in the image, and Figure c is a schematic diagram of calculating the area occupied by each unit and marking the unit with the highest proportion;

[0038] Figure 5 Schematic diagram of T2WI, T1ρ-DGE, CET1 scan and immunohistochemical staining results of a rat in the embodiment; wherein, Figure a is a T2WI scan, Figure b is a T1ρ-DGE scan, Figure c is a CET1 scan, Figure d is a section of the region of interest stained by H&E under a 200x microscope, Figure e is a section of the region of interest stained by VEGF under a 200x microscope, Figure f is a section of the region of interest stained by HIF-1α under a 200x microscope, Figure g is a section of the region of interest stained by H&E under a 400x microscope, Figure h is a section of the region of interest stained by VEGF under a 400x microscope, and Figure i is a section of the region of interest stained by HIF-1α under a 400x microscope. DETAILED DESCRIPTION

[0039] The present invention is described in detail below with reference to the accompanying drawings and specific embodiments. The following examples are implemented under the premise of the technical solution of the present invention, provide detailed implementation methods and specific operating procedures, and will help those skilled in the art to further understand the present invention. It should be pointed out that the scope of protection of the present invention is not limited to the following embodiments, and a number of adjustments and improvements made under the premise of the concept of the present invention all fall within the scope of protection of the present invention.

[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application pertains. The terms used herein are for the purpose of describing the embodiments of this application only and are not intended to limit this application.

[0041] The present invention provides an imaging system based on dynamic glucose enhancement technology, comprising:

[0042] Module M1: Perform magnetic resonance imaging on the patient's head to obtain T1ρ-DGE imaging, T2WI imaging, and CET1WI imaging;

[0043] Module M2: align T2WI imaging with CET1WI imaging and resample to T1ρ-DGE imaging to obtain non-overlapping areas, which are the mismatch areas;

[0044] Module M3: Calculate the signal increase of the mismatched area compared with the contralateral normal brain tissue area in T1ρ-DGE imaging;

[0045] Module M4: Identify areas of abnormal glucose metabolism based on the difference in signal amplification between T1ρ-DGE imaging and CET1WI imaging.

[0046] Preferably, the T1ρ-DGE imaging is T1ρ-weighted dynamic glucose-enhanced imaging, T2WI imaging is T2-weighted imaging, and CET1WI is contrast-enhanced T1-weighted imaging. T1ρ-DGE imaging involves the injection of a certain proportion of dextrorotatory glucose solution, which can cause delayed enhancement in the tumor area, unlike T2WI imaging following injection of a gadolinium contrast agent. This technology reflects the glucose uptake and metabolism inside and outside tumor tissue cells by capturing the intracellular and extracellular hydroxyl exchange.

[0047] Preferably, in module M1, the pretreatment for T1ρ-DGE imaging comprises: injecting a dextrorotatory glucose solution into the patient's elbow vein; wherein the injection dose is 2.5-3.5 mL / kg and the injection rate is 0.05-0.15 mL / min. In some embodiments, the dextrorotatory glucose solution is a solution of dextrorotatory glucose dissolved in phosphate buffered saline (PBS; 10 mM H2PO4 - / HPO4 2- , pH = 7.2) and placed in a nuclear magnetic resonance tube. All solutions were set at 37°C.

[0048] Preferably, the mass percentage of the dextrose solution is 5%-10%.

[0049] Preferably, in module M1, the pretreatment for CET1WI imaging includes: injecting a gadolinium solution into the patient's cubital vein at a dose of 0.05-0.15 mmol / kg and an injection rate of 1.5-2.5 mL / s. Preferably, the gadolinium solution is Gd-DTPA (Magnevist; Bayer-Schering, Berlin, Germany).

[0050] Preferably, the concentration of the gadolinium solution is 0.5 mmol / mL.

[0051] Preferably, in module M1, the T2WI imaging is a plain scan, and does not require injection of contrast agent.

[0052] Preferably, in module M1, the T1ρ-DGE imaging acquisition parameters are as follows: repetition time (TR) / echo time (TE) = 2300 / 69.6 ms, field of view (FOV) = 60×36 mm, matrix = 96×40, slice thickness / slice spacing = 2.8 / 0.2 mm, number of excitations (NEX) = 6, spin lock frequency = 500 Hz, spin lock time (TSL) = 50 ms, number of measurements = 35; the T2WI imaging acquisition parameters are as follows: T R / TE=7964 / 73.2ms, FOV=60×42mm, matrix=192×160, slice thickness / slice spacing=1.8 / 0.2mm, echo train length (ETL)=24, NEX=2; the CET1WI imaging acquisition parameters are as follows: TR / TE=1750 / 16.1ms, FOV=60×42mm, matrix=288×256, slice thickness / slice spacing=2.8 / 0.2mm, ETL=6, NEX=2.

[0053] Preferably, in module M3, the signal increase is an increase in intensity ratio (DGEρ).

[0054] Preferably, the intensity ratio DGEρ is the change in relative signal intensity (SI) at time point t in T1ρ-DGE imaging, and its calculation formula is as follows:

[0055]

[0056] Where S(t) is the signal intensity at time t, and Sref is the reference signal intensity obtained before the injection of the D-glucose solution. Specifically, the intensity ratio DGEρ is determined by the relative SI difference between the T1ρ-DGE SI (S(t)) obtained at time t and the reference signal (Sref) obtained by averaging the T1ρ-DGE SI before glucose injection.

[0057] Preferably, in module M4, the difference in signal amplification between the T1ρ-DGE imaging and the CET1WI imaging is that the signal amplification of the T1ρ-DGE imaging is greater than 20% and no signal amplification is observed in the CET1WI imaging.

[0058] Preferably, a surgical resection range guidance plan is generated based on the quantitative positioning results of the abnormal glucose metabolism area, and the abnormal glucose metabolism area is defined as the peritumoral area.

[0059] Example

[0060] This embodiment discloses an imaging method based on dynamic glucose enhancement technology, which uses non-invasive dynamic glucose metabolism imaging technology to obtain the real glucose metabolism in the tumor, provide the early infiltration boundary of glioma that cannot be displayed by traditional imaging, and quantitatively guide the surgical resection range. Figure 1As shown, the method includes the following steps:

[0061] Step S1: Inject the pre-prepared optimal concentration of dextrose solution intravenously into the patient. The optimal concentration of dextrose solution is the optimal concentration after preliminary experimental exploration. The preliminary experiment was to anesthetize healthy rats aged 6-10 weeks by intraperitoneal injection of 3% sodium pentobarbital (dose 30 mg / kg), and use a heating pad to keep warm throughout the experiment. After anesthesia, dynamic glucose enhanced scanning was performed before and after intraperitoneal injection of 5%, 10%, and 15% dextrose solution and normal saline control. After processing the scanned images using MATLAB (MathWorks, Natick, MA, USA), two experienced neuroradiologists compared and analyzed the images before and after the injection of dextrose, evaluated the image quality at different dextrose concentrations, and finally selected the optimal concentration of dextrose solution as the contrast agent for the experiment. Before the injection of the dextrose solution, the following steps were included: dissolve dextrose in phosphate buffered saline (PBS; 10mM H2PO4 - / HPO4 2- , pH = 7.2) were prepared into different concentrations and placed in NMR tubes. All solutions were set at 37 ° C. Figure 2 As shown (the Chinese translation of saline is physiological saline; the Chinese translation of glucose is glucose), after testing the average signal values ​​of different solution models, it can be observed that 5% and 10% dextrose solutions have better visual effects, especially 10% dextrose solution presents the best visual effect.

[0062] Step S2: The patient's head is scanned using T1ρ-weighted dynamic glucose enhancement (T1ρ-DGE) to obtain T1ρ-DGE images. T1ρ-DGE involves injecting a pre-prepared optimal concentration of dextrose into the patient's cubital vein at a dose of 3 mL / kg and an injection rate of 0.1 mL / min. This technique produces delayed enhancement in the tumor region, unlike gadolinium contrast agents. This technique captures intracellular and extracellular hydroxyl exchange, reflecting the glucose uptake and metabolism within and outside tumor tissue cells. Furthermore, a head scan is performed to obtain T2-weighted imaging (T2WI) and contrast-enhanced T1-weighted imaging (CET1WI). CET1WI involves injecting Gd-DTPA (Magnevist; Bayer-Schering, Berlin, Germany) into the patient's cubital vein at a concentration of 0.5 mmol / mL, a dose of 0.1 mmol / kg, and an injection rate of 2 mL / s. The skull scanning parameters were as follows: (1) T1ρ-DGE imaging: repetition time (TR) / echo time (TE) = 2300 / 69.6 ms, field of view (FOV) = 60 × 36 mm, matrix = 96 × 40, slice thickness / slice spacing = 2.8 / 0.2 mm, number of excitations (NEX) = 6, spin-lock frequency = 500 Hz, spin-lock time (TSL) = 50 ms, number of measurements = 35; (2) T2WI: TR / TE = 7964 / 73.2 ms, FOV = 60 × 42 mm, matrix = 192 × 160, slice thickness / spacing = 1.8 / 0.2 mm, echo train length (ETL) = 24, NEX = 2; (3) CET1WI: TR / TE = 1750 / 16.1 ms, FOV = 60 × 42 mm, matrix = 288 × 256, slice thickness / spacing = 2.8 / 0.2 mm, ETL = 6, NEX = 2.

[0063] Step S3: Based on the T1ρ-DGE scan signal gain and the difference from conventional enhanced imaging, the abnormal glucose metabolism area outside the tumor is identified. The signal gain is the increase in the intensity ratio (DGEρ) of the mismatched area shown on the T1ρ-DGE image compared to the contralateral normal brain tissue area. The mismatched area is the non-overlapping area observed after registering the T2WI and CET1WI images and resampling them to the T1ρ-DGE image space. The difference from conventional enhanced imaging is the signal gain of the contralateral normal brain tissue area compared to the mismatched area not observed on CET1WI imaging.

[0064] DGEρ is the change in relative signal intensity (SI) at time point t in T1ρ-DGE imaging. It is determined by the relative SI difference between the signal intensity T1ρ-DGE SI (S(t)) acquired at time point t and the reference signal intensity (Sref) obtained by averaging T1ρ-DGE SI before glucose injection. The calculation formula is as follows:

[0065]

[0066] Three 1 mm2 areas were manually outlined in the tumor, mismatched area, and contralateral normal brain tissue. 2 The region of interest (ROI) was recorded. The T1ρ-DGE SI within the ROI was recorded, and the corresponding DGEρ(t) was calculated. All T1ρ-DGE time courses and images were generated by the average of five consecutive measurements for each data point. The T1ρ-DGE image showed that the DGEρ in the mismatched area increased by 20% or more compared with the contralateral normal brain tissue area, while no signal enhancement was observed in this area on CET1WI. At this time, the mismatched area shown on the T1ρ-DGE image is an abnormal metabolic area. The difference from traditional enhanced imaging is that the abnormal metabolic area scanned by DGE has no enhancement on the CET1WI image.

[0067] Step S4: Generate a surgical resection range guidance plan based on the results of the abnormal glucose metabolism area positioning. The abnormal glucose metabolism area is defined as the peritumoral area.

[0068] See also Figure 3 , for example, Figure 3 The present invention provides a method for imaging glioma-bearing rats based on a DGE imaging method, which is obtained by using T2WI, T1ρ-DGE, and CET1WI, and a dynamic curve of T1ρ / CET1 mismatched ROI (injection is translated into Chinese as injection; number of phase is translated into Chinese as the number of phases). Figure a represents a CET1WI image, Figure b represents a T2WI image, Figure c represents a T1ρ-DGE image, Figure d represents a schematic diagram of the outline in the T1ρ-DGE image, and Figure e represents the dynamic curve change of T1ρ / CET1 mismatched ROI, where ROI1 corresponds to the normal brain tissue area; ROI2 corresponds to the tumor parenchyma area; and ROI 3 corresponds to the mismatched area. Three 1mm2 areas were manually outlined in the tumor, the mismatched area, and the contralateral normal brain tissue. 2Region of interest (ROI). The dynamic curve of the T1ρ / CET1 mismatch ROI showed a significant increase in SI in period 5 (about 90 seconds), a slight decrease in period 15-45 (about 300-800 seconds) after glucose injection, and a high SI plateau period during the period. The T1ρ-DGE SI within the ROI was recorded, and the corresponding DGEρ(t) was calculated. All T1ρ-DGE time courses and images were generated by the average of five consecutive measurements for each data point. The T2WI and CET1WI images were aligned and resampled to the T1ρ-DGE image space. The mismatch area was defined as the peritumoral area where the T1ρ-DGE image showed an increase in DGEρ (20% or more compared to the contralateral area) while no enhancement was observed on CET1WI.

[0069] See also Figure 4 , for example, Figure 4 A schematic diagram of manually outlining the T1ρ / CET1 mismatch area based on overlapping imaging obtained based on a DGE imaging method provided in this embodiment is shown. Figure a is a schematic diagram of the T1ρ / CET1 image mismatch area, Figure b is a schematic diagram of establishing a coordinate system in the image; Figure c is a schematic diagram of calculating the area occupied by each unit and marking the unit with the highest proportion. The coordinate system is established with the intersection of the long axis and the short axis of the tumor as the origin. The ITK-SNAP software (version 3.6.0) is used to calculate the area of ​​each unit (1×1mm 2 ) and place a black mark on the unit with the highest proportion to analyze the signal space position of the image.

[0070] See also Figure 5 , for example, Figure 5 The T2WI, T1ρ-DGE, CET1WI scans and immunohistochemical staining results of a rat numbered 8 obtained based on a DGE imaging method provided in this embodiment are shown. Figures 6a-c are T2WI, T1ρ-DGE and CET1. The mismatched area of ​​interest indicated by the red arrow is clearly visible in T1ρ-DGE imaging, but is not shown in Figure a (T2WI) and Figure c (CET1WI). Figures 6d-f are sections of the area of ​​interest stained with H&E, VEGF and HIF-1α under a 200x microscope. Figures 6g-i are sections of the area of ​​interest stained with H&E, VEGF and HIF-1α under a 400x microscope. Pathological changes in the T1ρ / CET1 mismatched area were observed in the area marked with a red box. In the T1ρ / CET1 mismatched area, malignant microstructures of neurons and infiltration of tumor cells in the VR gap were observed.

[0071] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art may make various variations or modifications within the scope of the claims, which do not affect the essence of the present invention.

Claims

1. An imaging system based on dynamic glucose enhancement technology, characterized in that: include: Module M1: Perform magnetic resonance imaging on the patient's head to obtain T1ρ-DGE imaging, T2WI imaging, and CET1WI imaging; Module M2: align T2WI imaging with CET1WI imaging and resample to T1ρ-DGE imaging to obtain non-overlapping areas, which are the mismatch areas; Module M3: Calculate the signal increase of the mismatched area compared with the contralateral normal brain tissue area in T1ρ-DGE imaging; Module M4: Identify areas of abnormal glucose metabolism based on the difference in signal amplification between T1ρ-DGE imaging and CET1WI imaging.

2. The system according to claim 1, wherein: In module M1, the pretreatment of T1ρ-DGE imaging includes: injecting dextrorotatory glucose solution into the patient's body through the elbow vein; the injection dose is 2.5-3.5 mL / kg, and the injection rate is 0.05-0.15 mL / min.

3. The system according to claim 2, characterized in that The mass percentage of the dextrose solution is 5%-10%.

4. The system according to claim 1, wherein: In module M1, the pretreatment of CET1WI imaging includes: injecting gadolinium solution into the patient's body through the elbow vein; the injection dose is 0.05-0.15 mmol / kg, and the injection rate is 1.5-2.5 mL / s.

5. The system according to claim 1, wherein: In module M1, the T1ρ-DGE imaging acquisition parameters were as follows: repetition time / echo time = 2300 / 69.6 ms, field of view = 60 × 36 mm, matrix = 96 × 40, slice thickness / slice spacing = 2.8 / 0.2 mm, number of excitations = 6, spin-lock frequency = 500 Hz, spin-lock time = 50 ms, and number of measurements = 35.

6. The system according to claim 1, wherein: The T2WI imaging acquisition parameters are as follows: repetition time / echo time = 7964 / 73.2 ms, field of view = 60×42 mm, matrix = 192×160, slice thickness / slice spacing = 1.8 / 0.2 mm, echo train length = 24, and number of excitations = 2; the CET1WI imaging acquisition parameters are as follows: TR / TE = 1750 / 16.1 ms, FOV = 60×42 mm, matrix = 288×256, slice thickness / slice spacing = 2.8 / 0.2 mm, echo train length = 6, and number of excitations = 2.

7. The system according to claim 1, wherein: In module M3, the signal increase is the increase in the intensity ratio DGEρ.

8. The system according to claim 7, characterized in that The intensity ratio DGEρ is the change in relative signal intensity SI at time point t in T1ρ-DGE imaging, and its calculation formula is as follows: Wherein, S(t) is the signal intensity obtained at time point t, and Sref is the reference signal intensity obtained before the injection of the D-glucose solution.

9. The system according to claim 1, wherein: In module M4, the difference in signal amplification between the T1ρ-DGE imaging and the CET1WI imaging is that the signal amplification of the T1ρ-DGE imaging is greater than 20% and no signal amplification is observed in the CET1WI imaging.

10. An imaging method based on dynamic glucose enhancement technology, characterized in that: The following steps are involved: Step S1: Perform magnetic resonance imaging on the patient's head to obtain T1ρ-DGE imaging, T2WI imaging, and CET1WI imaging; Step S2: registering the T2WI imaging with the CET1WI imaging and resampling them to T1ρ-DGE imaging to obtain the non-overlapping area, which is the mismatch area; Step S3: calculating the signal increase of the mismatched area compared with the contralateral normal brain tissue area in T1ρ-DGE imaging; Step S4: Identify abnormal glucose metabolism areas based on the difference in signal amplification between T1ρ-DGE imaging and CET1WI imaging.